Navigation Links
MAP Pharmaceuticals Appoints H. Ward Wolff to Board of Directors
Date:3/25/2008

MOUNTAIN VIEW, Calif., March 25 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced the appointment of financial executive H. Ward Wolff to its board of directors. Mr. Wolff brings over 25 years of financial experience to the board, where he will also serve on the audit committee.

Mr. Wolff is currently Executive Vice President and Chief Financial Officer at Richmond, Calif.-based Sangamo BioSciences, Inc. where he oversees the company's administrative, financial and business development activities and operations. He is also a member of the board of directors of Portola Pharmaceuticals, Inc.

"We are privileged to welcome someone with the depth and breadth of financial experience and knowledge of our industry that Ward brings to our board of directors and audit committee," said Timothy S. Nelson, President and Chief Executive Officer of MAP Pharmaceuticals. "We look forward to benefitting from his expertise as we advance our lead product candidates through clinical development and potential commercialization."

Mr. Wolff was previously Senior Vice President, Finance and CFO at Nuvelo, Inc., and Senior Vice President, Finance and CFO at Abgenix, Inc. until it merged with Amgen Inc. Prior to joining Abgenix, Mr. Wolff held financial management positions in both public and private emerging growth companies, including serving as Senior Vice President and CFO of DoubleTwist, Inc., a life sciences company. He began his career with Price Waterhouse, where he held a number of positions as a certified public accountant.

Mr. Wolff received an M.B.A. from Harvard Business School and a B.A. in Economics from the University of California, Berkeley.

About MAP Pharmaceuticals, Inc.

MAP Pharmaceuticals develops and plans to commercialize new therapies for children and adults who suffer from chronic conditions that it believes are not adequately treated by currently available medicines. The company applies its proprietary inhalation technologies to enhance the therapeutic benefits and commercial attractiveness of proven drugs while minimizing risk by capitalizing on their known safety, efficacy and commercialization history. MAP Pharmaceuticals has two drug candidates, Unit Dose Budesonide and MAP0004, in late stage development for the potential treatment of pediatric asthma and migraine respectively. MAP Pharmaceuticals' pipeline also includes a drug candidate in early clinical development for the treatment of asthma and chronic obstructive pulmonary disease.

Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com.


'/>"/>
SOURCE MAP Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Conatus Pharmaceuticals Appoints Anthony W. Fox, MD, Ph.D., as Chief Medical Officer
2. XTL Biopharmaceuticals Announces Financial Results for the Year Ended December 31, 2007
3. Dreier LLP Announces Class Action Lawsuit Against Vertex Pharmaceuticals Incorporated (VRTX)
4. Alseres Pharmaceuticals, Inc. Raises $5 Million
5. Galderma Announces HSR Clearance for Its Proposal to Acquire CollaGenex Pharmaceuticals
6. Transcept Pharmaceuticals to Present at the BioCentury Future Leaders in the Biotech Industry Conference
7. Law Offices of Howard G. Smith Announces Class Action Lawsuit Against Vertex Pharmaceuticals Incorporated
8. Sagent Pharmaceuticals Launches Ciprofloxacin Injection, USP, 5% Dextrose Premix Bag
9. Waters Offers U.S. Water Authorities Complimentary Drinking Water Testing for the Presence of Pharmaceuticals
10. Transdel Pharmaceuticals to Present at Cowen and Companys 28th Annual Health Care Conference
11. Arena Pharmaceuticals Lorcaserin for Obesity Passes Major Safety Milestone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... Cambridge, MA (PRWEB) , ... May 05, 2016 ... ... distinctions among workers’ compensation laws in all U.S. states and certain Canadian provinces ... (IAIABC) and the Workers Compensation Research Institute (WCRI). , The report, ...
(Date:5/5/2016)... ... May 05, 2016 , ... Long Island’s fastest growing comprehensive ... noted Long Island eye surgeon, Kathleen Van Valkenburg, MD as part of their ongoing ... Martin, MD, medical director and managing partner of North Shore Eye Care. , ...
(Date:5/5/2016)... Wis. (PRWEB) , ... May 05, 2016 , ... ... system to provide focused resources for veterinary professionals across the United States. The ... improving the lives of their patients and giving dog, cat and horse owners’ ...
(Date:5/5/2016)... ... May 05, 2016 , ... ... people’s every day living patterns, Amerec, a Seattle-based steam bath and sauna manufacturer ... app. , The user interface of the app, developed for both smartphones and ...
(Date:5/5/2016)... ... May 05, 2016 , ... When stiff and achy ... alleviate the pain that’s a common osteoarthritis (OA) symptom. Yet, numerous clinical studies ... with arthritis. , “Physical therapy exercises are commonly prescribed to individuals with ...
Breaking Medicine News(10 mins):
(Date:5/5/2016)... -- Progra m m e ... , s mosquito in Cayman Islands ... by 96 %   Oxitec and the Cayman Islands ... Aedes aegypti, the dangerous mosquito that spreads dengue, Zika and chikungunya, ... Grand Cayman .  MRCU, a global leader in mosquito control, is planning ...
(Date:5/5/2016)... 2016 Research and Markets has announced the ... 5 EU Markets"  report to their offering.  ,     (Logo: ... on the current Positron Emission Tomography (PET) scanner and cyclotron ... which includes France , Germany ... and the United Kingdom . ...
(Date:5/5/2016)... DUBLIN , May 5, 2016 /PRNewswire/ ... the addition of the  "Europe Thalassaemia Market ... to their offering.       (Logo: ... research Europe Thalassaemia Market and Competitive Landscape ... Thalassaemia pipeline products, Thalassaemia epidemiology, Thalassaemia market ...
Breaking Medicine Technology: